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Abstract 
Rationale  
Emergence of synthetic cannabinoids (SCBs) in herbal smoking mixtures is a public health concern. 
New SCB’s such as 5f-AKB48 and 5F-PB-22 have been detected in French seizures and in sudden 
death post mortems in the US.  
Objectives  
The aim was to describe development of dependence on herbal smoking mixtures containing the 
SCB’s, 5f-AKB48 and 5F-PB-22 and subsequent withdrawal syndromes.  
Methods 
Dependent users of herbal smoking mixtures known to contain the SCB’s 5f-AKB48 and 5F-PB-22 
with an average Severity of Dependence Score (SDS) of 13 were interviewed using a structured 
guide (three males/three females). Narratives were analysed using the Empirical Phenomenological 
Psychological (EPP) five step method.  Six themes with 68 categories emerged from the analysis.  
Results  
Themes are illustrated as 1) Networks and Product Availability; 2) Drivers and Motives for Use; 3) 
Effect and Pathways toward Dependence; 4) Poly Substance Use and Comparisons to Natural 
Cannabis; 5) Dependence and Withdrawal and 6) Self-detoxification Attempts.  Two higher levels of 
abstraction above these theme-levels emerged from the data, with sole use of herbal smoking 
mixtures containing 5f-AKB48 and 5F-PB-22 centering on the interplay between intense cravings, 
compulsive all-consuming seeking, use and re-dose behaviours, and fear of the psychiatric and self-
harms caused when in withdrawal.  
Conclusions 
This is the first study describing dependence and withdrawal experiences in users dependent on 5f-
AKB48 and 5F-PB-22. Given the potential for adverse psychiatric and physical consequences of 
dependent use, further development of specific clinical responses and clinical research around 
toxicity and withdrawal severity are warranted.  
Key Words 
Synthetic cannabinoid; 5f-AKB48; 5F-PB-22; Herbal cannabis, Spice, withdrawal 
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Introduction 
The phenomenon of commercially available psychoactive products containing one or more synthetic 
cannabinoids (SCBs) in herbal smoking mixtures remains a serious public health concern (Brents 
and Prather 2014; Gunderson et al. 2012; Seely et al. 2012; Spaderna et al.  2013). Known as ‘K2, 
Spice and Kronic’ (Bright et al. 2013; Baumann et al. 2014; Fantegrossi et al. 2014), an ever diverse 
range of SCBs are manufactured and designed for circumvention of contemporary legislative 
controls (Vandrey et al. 2012).  The occurrence of SCBs was recognised in Europe as early as 2004 
when sold as ‘legal highs’ or ‘herbal highs’ (Bryner 2010; Deluca et al. 2009; Griffiths et al. 2010; 
Schifano et al. 2009; Seely et al. 2011). Diverse forms of manufacture are evident with SCBs 
sprayed onto plant material (generally about 3g), and subsequently dried, crushed and packaged as 
powdered, loose leaf or pre rolled mixtures (Zuba et al. 2011; Kikura-Hanajiri, et al. 2011).  Many 
European nations (Austria, Germany, France, Luxembourg, Poland, Lithuania, Sweden and Estonia) 
took legal actions to ban or control SCBs by 2009 (EMCDDA 2009), with other nations (United 
States (US), Australia, New Zealand) following suit (Dargan et al. 2011). Trends in use have 
displaced outside of Europe, and to countries including the United States (US), Australia, New 
Zealand, Japan, and Taiwan (Fattore and Fratta 2011; Grigoryev et al. 2011a,b; Seely et al. 2011).  
Despite efforts to regulate and reduce harm, use of herbal smoking mixtures containing SCBs have 
been reported as popular among Australian young adults, and particularly those who have previously 
used cannabis (Barratt et al. 2013).  US longitudinal data in 2015 however indicates a downward 
trend in popularity among both school aged children since 2013 (Johnston et al. 2015) and in college 
students (Egan et al. 2015).  
SCBs in contrast to phytocannabinoids (delta-9-tetrahydrocannabinl or THC) are high 
potency, high efficacy cannabinoid receptor full agonists (Lindigkeit et al. 2009; Tuv et al. 2012; 
Vardakou et al. 2010). Commonly identified SCBs such as JWH-018, JWH-073 and CP-47,497 bind 
and activate the cannabinoid receptors CB1R and CB2R with exceptional potency and efficacy 
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(Brents and Prather 2014; Gunderson et al. 2012; Seely et al. 2011).  Generally they exhibit similar 
effects to high dose cannabis, but are potentially more harmful (Hermanns-Clausen et al. 2013). 
SCBs are constantly innovating, with new generation designer cannabinoids emerging such as the 
aminoalkylindole JWH-073 (Auwärter et al. 2009; Lindigkeit et al. 2009), the hexyl homolog JWH-
019 (Dresen et al. 2011), and the more recent aminoalkylindoles, JWH-250 (Westphal et al. 2010) 
and JWH-398 (Hudson et al. 2010). Other market entries since 2010 include JWH-015, JWH-122, 
HU-210 and AM-694 (EMCDDA 2009; Ernst et al. 2011). More recently, 5F-AKB-48 was detected 
in French seizures (Roussel et al. 2015) and 5F-PB-22 in sudden deaths post mortems in the US 
(Behonick et al. 2014).  
Concerns around use of SCBs are compounded by the fact that these ever diverse range of 
new designer cannabinoids have the potential to cause significant adverse events following use and 
have not been rigorously tested in human clinical trials (Auwarter et al. 2009; Hillebrand et al. 2010; 
Seely et al. 2012). Clinical case presentation and user reporting of negative medical, psychiatric and 
social consequences is evident (Spaderna et al. 2013). Chronic use of SCBs can result in serious 
cognitive impairment and development of dependence (Fattore and Fratta 2011; Vardakou et al. 
2010; Zimmermann et al. 2009). The aim of this study was to describe user’s experiences of 
development of dependence on 5f-AKB48 and 5F-PB-22, and their subsequent experiences of 
attempting to withdraw. There is little published data regarding this phenomenon, despite withdrawal 
units and hospitals around the world providing case examples of the wide range of withdrawal 
syndromes ranging from very mild to that of psychotic symptoms and seizures, despite the reporting 
of smoking of similar amounts of herbal smoking mixtures (Zimmerman et al. 2009; Vearrier and 
Osterhoudt 2010; Müller,et al. 2010a; Hurst et al. 2011; Castellanos et al. 2011; Schneir et al. 2011; 
Van der Veer and Fiday 2011; Simmons et al. 2011; Tung et al. 2012; Gunderson et al. 2012; 
Bebarta et al. 2012; Berry-Caban et al. 2013; Rominger et al. 2013).  
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Methods 
The study was undertaken in 2015 in the north-east of the Republic of Ireland, as part of a larger 
research project investigating the availability and use of herbal smoking mixtures.  At the time, 
community care and mental health services reported concern for cross border drug tourism of novel 
psychoactive substances (NPS), littering of herbal product paraphernalia, increased crisis 
presentations at emergency health services and youth deaths by suicide speculated to be linked to 
psychotic symptoms when in withdrawal. 
A structured interview guide was developed by the research team on basis of extant available 
literature on SCBs, and active consultation with key professionals operating (n=3) in the area. 
Participants identified as using the available herbal mixtures containing 5f-AKB48 and 5F-PB-22 
were recruited with assistance from a local community outreach worker who acted as gatekeeper. 
Dependent users were screened for inclusion based on the Severity of Dependence Screener (SDS) 
(Gossop et al. 1995) which is a 5-item questionnaire, with scores of over 7 deemed to indicate 
dependence in the past 12 months. This screening tool has been used in a previous SCB study to 
distinguish between casual and dependent users (Gunderson et al. 2014).  Three male (aged 17-38 
years) and three female (20-42 years) dependent users of mixtures containing 5f-AKB48 and 5F-PB-
22 were interviewed. The average SDS score was 13, and with two scoring the maximum score of 15 
(one male, one female), two scoring 13 (two males), two female scores of 9 and 13 respectively.    
The study was conducted in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki, and the institute’s ethical policies for conducting research. All participants 
received an information sheet and gave written informed consent prior to the interview. All were 
assured of confidentiality and anonymity, and that they could withdraw from the study if requested. 
In depth interviews of 30-90 minutes were conducted in a private room at the community service 
setting, and captured illustrative data pertaining to the user’s experiences of dependence and 
withdrawal phenomena. Audio recordings were destroyed post transcription.  
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The data-set was analysed using the Empirical Phenomenological Psychological (EPP) five 
step method (Karlsson 1995). This approach is underpinned by Husserl’s (1970) phenomenology 
theory, and focused on the realist description of the ‘life world’ user’s experience of dependence 
trajectories and withdrawal syndromes. See Table 1. 
Insert Table 1 about here 
Six themes emerged from the analysis. During the final step in the analysis process, two additional 
higher levels of abstraction above the theme-level emerged from the data, firstly with use of herbal 
smoking mixtures centering on the interplay between intense cravings, compulsive all-consuming 
drug seeking and using behaviours, and secondly inability to cease use with fear of the psychiatric 
harms caused when in withdrawal. The raw data were re-read by both members of the research team 
with these two concepts described by the majority participants in distinct ways. 
 
Results  
Networks and Product Availability 
A variety of products containing 5f-AKB48 and 5F-PB-22 were in circulation (‘Clockwork Orange’, 
‘Happy Joker’). Online sourcing of information and bulk purchasing via web retailers, sourcing via 
local market retail, border drug tourism and door to door delivery were described. One participant 
described the use of car ‘blaring loud music like the ice-cream man’ as indicating presence of dealers 
in the estate. Awareness of potential adverse consequences of use was low and primarily reliant on 
perception of safety grounded in legal status, informal peer user dissemination, and if accessing 
community services on the provision of harm reduction leaflets by staff.   
‘It shouldn’t be legal. It shouldn’t be allowed, it is terrible, it’s killing us all.’ 
Participants described spending between €60 -200 per week for personal use. Some described large 
debts accruing over short timeframes due to compulsive use.   
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‘I could use three or four bags a day. They give it out on tick, these dealers like. That 
could go on until you run up a bill of maybe €300 or €400, it’s crazy’.  
Some participants described spending their parent’s money as well as their own social benefit. Many 
described personal neglect due to the cost involved.  
‘Maybe near €200 euro. I have often seen myself starving and buying it’.  
Alternative income generation and diversification into dealing was viewed to fuel continued 
availability, social reinforcement of use and clustering of ‘pockets of user networks’ within certain 
estates. Members of these user networks were described as ranging from as young as 13 or 14 years, 
up to early forties, with increasing patterns of use among females and older individuals.   
‘I’d say 70% of XXXX [estate] that, the oldest who smokes it in the park is the lads 
mother, and the oldest that smokes it is about 42. It doesn’t go past 42 years of age.’  
 
Drivers and Motives for Use 
Widespread availability and affordability (€15-20 per one gram bag) appeared first and foremost as 
driver for introduction and subsequent use.  Boredom and peer socialisation was mentioned by all 
participants as stimulating initial experimentation.  
‘Pure boredom. Sitting at home smoking, sure you’re doing nothing anyway, just lying 
about’.  
Participants reported smoking with no reports of insufflation or injecting. Two reported using a 
‘bong’, with others rolling up with very little tobacco added. Mixed opinions were evident with 
regard to preferences between rolling up and use of a bong.  
‘Through the bong, it’s the only way I do it. I smoke it pure and that’s the worst way of 
doing it. You’re getting that full hit of everything.’  
In addition to smoking for intoxication purposes (both dissociation and psycho-stimulant), some used 
to relieve anxiety and boost low mood.  
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‘I would be a worrier. It would make it better, it freezes it.’ 
One participant described use of herbal as quelling voices in their head. 
‘There are times when I hear voices in my head telling me to do these things, telling me 
suicidal thoughts. When I smoke the herbal it seems to kill the voice.’ 
 
Effect and Pathways toward Dependence  
First-time experimentation was described as an intensely pleasurable experience despite nausea. All 
reported intense desire to repeat the experience again.  
‘High as a kite, Felt brilliant, It was just the best feeling I’ve ever had. You are just 
feeling so happy, so “up there”. 
Participants described ‘warm, happy feelings’, which occurred within two-10 seconds, receded over 
seven-20 minutes depending on user tolerance and length of time using the product, and was rapidly 
replaced by feelings of agitation, restlessness and desire to re-dose during the comedown.  
‘Warm feelings, feel brilliant, but then when that feeling goes away, bad. Start feeling 
angry….’ 
Differences in effect were observed, ranging from dissociation to psycho-stimulation, and attributed 
to the lack of consistency in product quality and content, and the combinations of 5f-AKB48 and 5F-
PB-22.  
‘You could be chilled out with that one [pointed to packet], you know relaxed. And that 
one [pointed] your head could be racing.’  
The psycho-stimulant effect of herbal smoking mixtures was characterised by motor restlessness, 
fear, paranoia and aggression.  
‘When you are stoned [on herbal] you’re not relaxing, you’re jumping you are flinching, 
like those kinda movements [flinching and jerking movements], it is not good.’ 
(participant) 
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Experiences of unintentional overdose centred on intense chest pain and severe dissociation.   
‘You feel like a heart attack, that you are just gonna die all of a sudden. I’m in a very 
very deep sleep like.’  
Perceptions of the effect changed over time, from pleasure to user realisation of tolerance, unpleasant 
withdrawals and fears around stopping use.  
‘It is not the same buzz now. It’s the addiction, I don’t want it for the buzz. Something 
inside me needs it.’  
Participants described how the duration of effect reduced considerably over time, as tolerance 
increased. Re-dosing when use was established commonly occurred every 20 minutes within the 
smoking episode.   
‘When I first took it, it’d last an hour. Now 10 or 15 minutes it would be gone… then you 
do it all over again, all over again, all over again.’ 
 
Poly Substance Use and Comparisons to Natural Cannabis  
All described sole use of these mixtures containing 5f-AKB48 or 5F-PB-22 (or combined) and did 
not concurrently or sequentially consume any other illicit drugs or alcohol, with exception of when in 
withdrawals and using natural cannabis/alcohol to alleviate symptoms. All reflected on how they 
essentially replaced excessive alcohol use and illicit drug use, with the sole and dependent smoking 
of herbal mixtures.  
‘I had a problem with alcohol about five years ago. I went from one addiction and I 
walked straight into another one. This one is a lot harder to get off than the alcohol.’   
Many had used natural cannabis prior to introduction to mixtures containing 5f-AKB48 and 5F-PB-
22. Quality and potency of effect (‘the quick high’) was a factor in user decision-making, with 
reports of low availability of poor quality cannabis stimulating displacement to smoking herbal 
mixtures.  
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‘It was a quick high, couple drags and you are away…..with herbal you’ll get your high 
any time. ‘ 
 
Dependence and Withdrawal 
Patterns of established use occurred rapidly, and centred on regular daily smoking. Some only 
smoked at night (often in response to withdrawals) and were able to attend training activities during 
the day. Three described using alone, and the remainder in small groups, almost always indoors in 
private homes.  
‘I would do it on my own too, just to get a bit on me own.’  
Participants described using between one and four grams per day, with volume of use increasing 
quickly following first-time experimentation. Compulsive re-dosing occurred despite recognition of 
loss of control, awareness of tolerance and fears around adverse effects.  
‘I use three gram a day. That’ll do me just one day and a 1gram bag is gone in an hours’ 
time. That’s how bad it is. I won’t stop until it is gone. I know it’s killing me. I won’t stop 
it, I just can’t’.  
Many described rapid development of thoughts and cravings about smoking first thing in the 
morning, with one participant walking up in the middle of the night to smoke. This thought-process 
was observed to occur quite quickly following initial patterns of use of these mixtures.  
‘Every 2-3 hours, it is like in a routine, it has your head in a routine. If you told me I’d be 
dead tomorrow morning from that herbal, I still couldn’t give it up. That herbal still has 
an awful hold on me.’ 
Acute physical withdrawal symptoms when attempting to restrict use were reported to include chest 
pains, chest pressure, tachycardia and palpitations, lower extremity pain and spasms, nausea, 
sweating and vomiting.   
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‘Pains and aches come in if you haven’t got it. Bad pains across my chest, my heart 
thumping everyday 100 miles an hour. Flat out thumping non-stop. Then your hands 
start to sweat.’ 
These symptoms were described as easily resolved by resumed smoking of herbal mixtures. 
‘If I haven’t got it I get the sickness in my stomach, the sweating starts, the weakness 
starts, the sickness comes then you get the cold shiver through you, but as soon as you 
get a smoke of the herbal you are back to normal.’ 
Psychological withdrawal symptoms including anxiety, agitation and paranoia were illustrated by 
participants.  
‘If you don’t have it you feel down, angry. Just bad all the time. Fighting with your 
family over money that they haven’t got. Just do anything to get it.’  
Over time all participants described general decrease in function characterised by loss of appetite, 
breathlessness, cardiac conditions requiring medication, skin ablations, tooth decay, tremors and 
insomnia, which were all exacerbated when attempting to reduce use. Difficulties in eating were 
most common. 
‘I’d just look at it [plate of dinner] and take one forkful and say get that away from me, 
or vomit. It is just that serious. Haven’t had a dinner in three or four weeks.’ 
Two reported personal awareness and concern for cognitive impairment, characterised by ability to 
concentrate and short term memory loss. Apathy was a defining characteristic and with associated 
negative aspects relating to education, training and employment.  
‘My attitude is just ridiculous, I’m lazy, don’t wanna do nothing.’ 
All expressed regret on smoking herbal mixtures given their experience. 
‘Herbal is a curse. I wish I could never see it or smoked it or smelled it or anything. It’s 
a curse on everybody in this town to be honest.’ 
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Self-detoxification Attempts 
All described a desire and intentions to stop using, and how the occurrence of unpleasant physical 
and mental withdrawal symptoms fuelled fears and created barriers to achieving abstinence. Efforts 
to successfully self-detoxify at home were also hampered by low personal resilience and perceived 
willpower, and widespread availability in the locality.  
‘I would love to stop. I stress out too much. The most I’ve really stopped it for is a day, 
or most of a day, or like before going to bed that day I’d have had one.’ 
Use of other substances such as alcohol and natural cannabis to assist detoxification attempts was 
common.  
‘I’d use a good bit of it [alcohol] to try not smoke anything.’ 
One participant described attempts to return to use of natural cannabis, which was viewed as a lesser 
of two evils, and more manageable in terms of resuming a normal existence.  
‘I am trying to get back on the weed, you can eat properly, you can sleep properly.’ 
Two commented that if they were incarcerated, they would be able to cease use. One participant 
described a self-detoxification attempt when in prison characterised by diarrhoea, insomnia, 
restlessness, agitation, and sweating, and which was concluded within three weeks but with lasting 
difficulty with sleeplessness.  
‘Diarrhoea, can’t sleep, walking the floors, waking every half hour. Wanting a smoke 
like. It took me a good eight weeks to just get my sleep back to normal like and it took me 
I’d say a good four weeks for me to be “me”.’ 
Suicidal ideation and suicide attempts during these times were described by four participants.  
 ‘I don’t wanna hurt meself, but it’s gonna come that far. ‘I just hate it. So hard to get off 
it, so hard to do anything. There’s only one way of getting off herbal and that’s taking 
yourself out of this life’. 
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Experiences of bereavement of peer users who had committed suicide were described by four 
participants. This contributed to intense fears around coming off herbal mixtures.  
‘I lost a brother last year over herbal, lost a best friend over herbal as well. He hung 
himself.  I know it’s the herbal that killed them, but I can’t stop.’  
Participants expressed desire for residential detoxification and with sufficient length of step down 
care.  
‘To get away from it I need to be put into a clinic. Completely away’.  
 
Discussion  
Studies on NPS in Ireland to date have largely centred on the pre and post legislative sale and supply 
of headshop products (Kavanagh et al. 2010), and recreational and problematic injecting use of the 
synthetic cathinone, Mephedrone (McElrath and Van Hout 2011; Van Hout and Bingham 2012; Van 
Hout and Brennan 2011a,b,c, 2012). This is the first study of its kind focusing on use of SCBs in 
Ireland.  Findings are consistent with other qualitative studies focusing on the use of SCBs in terms 
of availability, motives for use and effects conducted in the US (Arfken et al. 2014; Meshack et al. 
2013), New Zealand (Every-Palmer 2011), and with online communities of drug users (Kjellgren and 
Jonsson 2013; Spaderna et al. 2013; Soussan and Kjellgren 2014), whilst also adding to the 
previously understudied phenomena of development of dependence and withdrawal syndromes in 
users of the recently designed SCBs, 5f-AKB48 and 5F-PB-22. We recognise the limitations of this 
exploratory study given its smallscale and localised nature in a marginalised estate in the Republic.  
Of interest is the clustering of sole use of these SCBs amongst these users, and the rapid and harmful 
development of dependence for these individuals.   
We were committed to ensuring that the user’s experience was undistorted by any pre 
conceived research understanding in analysis (Levasseur 2003). Validity in the form of 
‘trustworthiness’ of the data (Lincoln and Guba 1985; Wallendorf and Belk 1989), was strengthened 
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by verification of extensive horizontal and vertical similarities across these realist descriptions of 
experiences and subsequent partial phenomenological psychological reduction (Karlsson 1995).  
Supporting prior literature (Fattore and Fratta 2011; Gunderson et al. 2012; Spaderna et al. 2013), 
reasons for initial experimentation centred on boredom, low awareness of risk and widespread 
availability of mixtures in this estate. Smoking was the only route of administration and in order to 
enhance the effect, rarely in combination with tobacco. Awareness of harm was low, and similar to 
other studies (EMCDDA 2009; Every-Palmer 2011; Fattore and Fratta 2011; Gunderson et al. 2012; 
Seely et al.  2012; Seely et al. 2011) underpinned by the initial belief that herbal smoking mixtures 
were safe and natural, and an acceptable potent alternative to natural cannabis. Acute differences 
between spectrum and intensity of synthetic and natural cannabis are present (Brents et al. 2011; 
2012; Spaderna et al. 2013), with the short lived psycho-stimulant effect and development of 
compulsive regular use within short time frames differing to the longer lasting effects of natural 
cannabis.  Some studies report that herbal SCB users prefer the effects of natural cannabis to the 
synthetic variety (Arfken et al. 2014; Winstock and Barratt 2013).  
First-time experiences were intensely pleasurable characterised by euphoria, calmness, 
relaxation and feeling of well-being despite nausea, and with desire to repeat (Fattore and Fratta 
2011; Kjellgren and Jonsson 2013; Schnier et al. 2011). Once all contents were smoked, happy and 
calm feelings receded and were replaced by feelings of agitation and restlessness. Whilst the reported 
effects are described in other studies (Fattore and Fratta 2011; Kjellgren and Jonsson 2013; Schnier 
et al. 2011), in contrast, solitary smoking of herbal mixtures was preferred within the private home 
setting.  Subjective and physiologic (both dissociative and psycho-stimulant) effects and duration 
reportedly varied depending on content of the mixture (Schifano et al. 2006, 2009; Winstock and 
Barratt 2013) with some containing 5f-AKB48 and 5F-PB-22 in combination. Acute physical 
withdrawal symptoms are similar to those reported in the literature (see Helander et al. 2013; Seely 
et al. 2011; Simmons et al. 2011), and included internal restless, urge to re-dose, chest pains and 
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pressure, tachycardia and palpitations, lower extremity pain and spasms, nausea, sweating and 
emesis. Long term use was characterised by loss of appetite, cognitive impairment, breathlessness, 
cardiac conditions, skin ablations, tooth decay, lethargy, apathy, tremors and insomnia.   
Most concerning in this study was the reporting of agitation, suicidal ideation and self-harm 
ideologies, and incidences of sibling and peer suicide during times of withdrawal and when 
attempted to restricted use or self-detoxify. Emergency hospital presentations have described 
presentations with severe agitation, panic attacks, tachycardia, nausea, paranoid ideation, and 
hallucinations post SCB use (Banerji et al. 2010; Bebarta et al. 2010; Sobolevsky et al. 2010; 
Vearrier and Osterhoudt 2010). SCB associated psychotic reactions (Castellanos et al. 2011; Every-
Palmer 2010, 2011; Schneir et al. 2011; Spaderna et al. 2013), are often the common reason for the 
seeking of medical assistance (Forrester, et al.,2011) and can be prolonged and persistent, and 
sometimes never remit (Berry-Caban et al. 2013; Hurst et al. 2011; Tung et al. 2012; Van der Veer 
and Fiday 2011).  Debates continue around whether use of herbal mixtures containing SCBs 
precipitates psychosis in individuals with and without history of psychotic disorders (Every-Palmer 
2010; 2011; Hurst et al. 2011; Müller et al. 2010a,b; Pierre 2011).  
Whilst research suggests the presence of three distinct groups of SCB users (marijuana users, 
casual users seeking to avoid detection, and naïve drug experimenters) (Seely et al. 2012), this study 
highlights the rapid addictive nature of herbal mixtures containing 5f-AKB48 and 5F-PB-22, where 
participants described quickly adopted dependent use patterns and routines. There appeared to be a 
blurring between comedown and withdrawal in user experiences over time. Development of 
dependence, tolerance over time, persistence of craving, continuous urge to consume despite adverse 
consequences, scarce attention to other interests or duties and clear withdrawal symptomatologies in 
the event of protracted high dose use are well-documented in the case of SCBs (Fattore and Fratta 
2011; Vardakou et al. 2010; Zimmermann et al. 2009). Dependent use in this study was characterised 
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by intense thought processes around seeking, using, re-dosing and sourcing, consumption at night in 
between sleeping, and the high SDS scores of participants.  
However despite efforts to try to stop, unsuccessful attempts at ceasing use (one to four days 
abstinent) and self-detoxifying were reported and often with use of alcohol and cannabis to manage 
symptoms. Withdrawal reactions in other studies reportedly resolve within a week (Zimmermann et 
al. 2009; Rominger et al. 2013).  Self-detoxification efforts in this study were further hampered by 
widespread social cues and contexts for use amongst networks of users and availability, alongside 
personal fears of psychosis and self-harm.  Abstinence symptoms differed from natural cannabis in 
terms of the significant medical and psychiatric consequences (Budney and Stanger 2012), but with 
withdrawal syndromes acting as a negative reinforcers for use (Coffey et al. 2002; Gillespie et al. 
2007; Chung et al. 2008). These symptoms resolved with resumed smoking of herbal mixtures. Of 
interest was that in contrast to SCB studies reporting poly substance use (Schifano et al. 2010; 
Vandrey et al. 2012; Winstock and Barratt 2013; Caviness et al. 2015), dependent users in this study 
smoked only the identified herbal mixtures containing 5f-AKB48 and 5F-PB-22, and used alcohol 
and cannabis only when attempting to self-detoxify in efforts to alleviate withdrawals. Severity of 
natural cannabis withdrawal has predictive validity in use of cannabis or other substances to alleviate 
symptoms (Copersino et al. 2006; Chung et al. 2008; Cornelius et al. 2008). The study highlights the 
need for the generation of evidence based medical and psychiatric treatment and detoxification 
protocols for this particularly severe form of synthetic cannabis withdrawal.  
 
Conclusion  
The ever changing composition of herbal smoking mixtures and uneven consistency in the diverse 
range of new SCB’s contributes to experiences of undesirable effects, psychiatric risks and the risks 
of accidental overdose (Uchiyama et al. 2010; Seely et al. 2012).  This is, to our knowledge, the first 
study describing the development of dependence and withdrawal syndrome in dependent users of the 
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new SCB’S, 5f-AKB48 or 5F-PB-22, and contributes to the previously understudied phenomena of 
dependent use and withdrawal from SCB’s.  The study whilst small-scale and localised to a 
marginalised estate in Ireland highlights the rapid development of tolerance, regular dependent use 
within short timeframes and acute withdrawal symptomatologies on cessation of use. Dependent use 
of mixtures containing SCBs is a concern given reporting of acute CNS and cardiovascular toxicity 
with severe cardiovascular, gastrointestinal and psychiatric sequelae (Gunderson et al. 2012; Brents 
and Prather 2014). The wide variability of structure and pharmacological effects of SCB’s, 
contributes to the recognition that mixtures containing SCBs should not be considered as 
homogenous products. Given the high affinity for the CB1R and CB2R receptor sites of some 
SCB’s, and the implications of this on toxicity or withdrawal severity, further research is required to 
identify which SCBs are particularly toxic and most likely to cause severe withdrawal subsequent to 
dependence. Findings on these SCBs 5f-AKB48 and 5F-PB-22 warrant consideration in terms of 
informing policy and public health responses in Ireland where widely available. Continued specific 
evidence based psychiatric and clinical responses to treat withdrawal syndromes should be situated 
within expedited inter-agency pathways for detoxification, addiction counselling, crisis intervention 
and family support for dependent users.  Training of key community and health professionals, and 
the design and implementation of harm reduction activity is also warranted.  
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Table 1 Empirical Phenomenological Psychological (EPP) five step method (Karlsson 1995) 
Step 1.  The data file was read three times by both members of the team so as to 
familiarise, identify psychological phenomena and achieve an overview of 
the dependence and withdrawal phenomenon in an unbiased and open 
manner, and in the absence of any specific hypothesis. Theoretical reflection 
was withheld at this step. 
Step 2.  
 
The text was subsequently divided into smaller meaning units (MU), without 
regard to syntax, and each time a new meaning, focus or topic was 
introduced 
Step 3. 
 
All MUs were transformed from the participants wording and restated by the 
research team in order to present the significant and implicit meaning of the 
dependence and withdrawal phenomena in objectivised terms. In order to 
obtain interpretative validity considerable efforts were made by the research 
team to ensure respect of the participants’ experience 
Step 4.  The restated MUs were then categorised by repeated consultation with the 
raw data, scrutinizing that the category itself was maintained, the 
understanding of what the phenomenon is (noema) and how it is expressed 
(noesis) and by considering specific characteristics and similarities in the 
dependence and withdrawal phenomena.  
Step 5.  The generated categories then formed part of an abstraction process in order 
to create more general and overarching themes through the patterns 
identified within related categories.  
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